Samson M K, Baker L H, Talley R W, Fraile R J, McDonald B
Cancer Treat Rep. 1978 Aug;62(8):1223-5.
Twenty-six patients with disseminated malignant melanoma were treated with intermittent bolus DTIC and actinomycin D in an escalating dose schedule, starting at 650 and 1 mg/m2 respectively. Courses were repeated at 3--4-week intervals. Twenty four patients were evaluable for toxicity and 22 were evaluable for response. Two patients (9%) had a complete remission lasting 7+ and 14 months, and three patients (14%) had a partial remission lasting 2+, 5+, and 14+ months. Nausea and vomiting, lasting 24 hours, was observed in 88% of patients, while diarrhea was noted in 17%. Stomatitis and alopecia were less frequently observed. All responses occurred at nonmyelosuppressive doses and in patients with visceral-predominant metastases. This schedule offers the patient the convenience of single-day treatment and less prolonged gastrointestinal intolerance. Further evaluation of this drug combination and schedule would appear to be indicated.
26例播散性恶性黑色素瘤患者接受了间歇性大剂量达卡巴嗪（DTIC）和放线菌素D治疗，剂量按递增方案给药，起始剂量分别为650mg/m²和1mg/m²。疗程每3 - 4周重复一次。24例患者可评估毒性，22例可评估疗效。2例患者（9%）完全缓解，持续时间分别为7个月以上和14个月；3例患者（14%）部分缓解，持续时间分别为2个月以上、5个月以上和14个月以上。88%的患者出现持续24小时的恶心和呕吐，17%的患者出现腹泻。口腔炎和脱发较少见。所有缓解均发生在非骨髓抑制剂量下，且发生在内脏为主转移的患者中。该方案为患者提供了单日治疗的便利，且胃肠道不耐受时间较短。似乎有必要对这种药物组合和方案进行进一步评估。
